Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer
- PMID: 34059350
- DOI: 10.1016/j.ygyno.2021.05.023
Oncologic outcomes in the era of modern radiation therapy using FIGO 2018 staging system for cervical cancer
Abstract
Background: The recently published ASTRO cervical cancer guidelines recommend the use of modern radiotherapy. Imaging is now incorporated in the updated FIGO 2018 staging with a new stage IIIC. This study aims to evaluate the oncologic outcomes and predictors of survival using FIGO 2018 staging in a cohort of patients treated in an era of high-precision image-guided radiotherapy.
Methods: We performed a retrospective cohort study of 216 adult cervical cancer patients treated with definitive chemoradiotherapy between 2010 and 2018. Eligible patients had non-metastatic cervical cancer treated at a single academic institution. All patients had pre-treatment MRI and CT/PET. Treatment protocol consisted of external beam intensity-modulated radiotherapy and 3D image-guided brachytherapy. Kaplan-Meier curves were used for survival analysis. Multivariate cox proportional-hazards model was performed to identify potential prognostic factors.
Results: Median age at diagnosis was 50 and median BMI was 26.4 kg/m2. Median follow-up time was 44.3 months. Five-year overall survival (OS), disease-free survival and loco-regional disease-free survival rates were 76.8%, 68.5% and 82.6%, respectively. FIGO 2018 showed better OS discrimination compared to FIGO 2009 classification. OS was increasingly worse with positive pelvic and para-aortic nodes (p < 0.001). In a multivariate prediction model, performance status (p = 0.044) and FIGO 2018 classification (stage III p = 0.016; stage IVA p = 0.010) were predictors of mortality; FIGO 2018 classification (stage III p = 0.003; stage IVA p = 0.001) was a predictor of any recurrence; MRI tumor diameter (p ≤ 0.001) and nodal metastases (p = 0.024) were predictors of loco-regional recurrence.
Conclusions: Integration of state-of-the-art imaging in cervical cancer staging and in radiotherapy planning leads to good loco-regional control rates, however distant recurrence remains an important issue. FIGO 2018 staging better reflects patient prognosis, highlighting the need for new treatment strategies for stage IIIC cervical cancer.
Keywords: Brachytherapy; Image-guided; Intensity-modulated; Magnetic resonance imaging; Positron-emission tomography; Radiotherapy; Uterine cervical neoplasms.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest No authors have conflicts of interest to disclose.
Similar articles
-
Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review.Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221086403. doi: 10.1177/15330338221086403. Technol Cancer Res Treat. 2022. PMID: 35341413 Free PMC article. Review.
-
The prognostic value of FIGO staging defined by combining MRI and [18F]FDG PET/CT in patients with locally advanced cervical cancer.Curr Probl Cancer. 2023 Dec;47(6):101007. doi: 10.1016/j.currproblcancer.2023.101007. Epub 2023 Sep 5. Curr Probl Cancer. 2023. PMID: 37684197
-
Less Than Whole Uterus Irradiation for Locally Advanced Cervical Cancer Maintains Locoregional Control and Decreases Radiation Dose to Bowel.Pract Radiat Oncol. 2019 Mar;9(2):e164-e171. doi: 10.1016/j.prro.2018.10.009. Epub 2018 Nov 2. Pract Radiat Oncol. 2019. PMID: 30395974
-
[Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy].Zhonghua Fu Chan Ke Za Zhi. 2015 Feb;50(2):125-30. Zhonghua Fu Chan Ke Za Zhi. 2015. PMID: 25877610 Chinese.
-
Comparison of global treatment guidelines for locally advanced cervical cancer to optimize best care practices: A systematic and scoping review.Gynecol Oncol. 2022 Nov;167(2):360-372. doi: 10.1016/j.ygyno.2022.08.013. Epub 2022 Sep 10. Gynecol Oncol. 2022. PMID: 36096973
Cited by
-
Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review.Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221086403. doi: 10.1177/15330338221086403. Technol Cancer Res Treat. 2022. PMID: 35341413 Free PMC article. Review.
-
Predictive value of number of metastatic lymph nodes and lymph node ratio for prognosis of patients with FIGO 2018 stage IIICp cervical cancer: a multi-center retrospective study.BMC Cancer. 2024 Aug 13;24(1):1005. doi: 10.1186/s12885-024-12784-8. BMC Cancer. 2024. PMID: 39138415 Free PMC article.
-
Stage migration and survival outcomes in patients with cervical cancer at Stage IIIC according to the 2018 FIGO staging system: a systematic review and meta-analysis.Front Oncol. 2024 Oct 1;14:1460543. doi: 10.3389/fonc.2024.1460543. eCollection 2024. Front Oncol. 2024. PMID: 39411135 Free PMC article. Review.
-
Early onset of severe lymphopenia during definitive radiotherapy correlates with mean body dose and predicts poor survival in cervical cancer.Cancer Biomark. 2022;34(1):149-159. doi: 10.3233/CBM-210292. Cancer Biomark. 2022. PMID: 35094986 Free PMC article.
-
Nomogram Predicting Overall Survival in Patients with FIGO II to III Squamous Cell Cervical Carcinoma Under Radical Radiotherapy: A Retrospective Analysis Based on 2018 FIGO Staging.Cancer Manag Res. 2021 Dec 29;13:9391-9400. doi: 10.2147/CMAR.S336892. eCollection 2021. Cancer Manag Res. 2021. PMID: 35002316 Free PMC article.